Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $50.0 million.

  • Axsome Therapeutics' Shares Outstanding (Diluted Average) rose 390.8% to $50.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.0 million, marking a year-over-year increase of 390.8%. This contributed to the annual value of $47.9 million for FY2024, which is 547.94% up from last year.
  • Per Axsome Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $50.0 million for Q3 2025, which was up 390.8% from $49.4 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $50.0 million for Q3 2025, and its period low was $38.3 million during Q1 2022.
  • In the last 4 years, Axsome Therapeutics' Shares Outstanding (Diluted Average) had a median value of $47.1 million in 2023 and averaged $45.3 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Shares Outstanding (Diluted Average) skyrocketed by 1357.0% in 2023, and later soared by 217.19% in 2024.
  • Axsome Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $40.7 million in 2022, then increased by 11.73% to $45.4 million in 2023, then increased by 5.48% to $47.9 million in 2024, then rose by 4.4% to $50.0 million in 2025.
  • Its last three reported values are $50.0 million in Q3 2025, $49.4 million for Q2 2025, and $48.9 million during Q1 2025.